

The supply of plasma-derived medicinal products in the future of Europe

Second edition

23-24
April 2024
Rome, Italy

CENTRO
NAZIONALE
SANGUE

 PLASMA
ITALIA
italiaplasma.it

with the patronage of



Ministero della Salute

Patient protection linked to SUPPLY WP6 recommendations

SYELDY LANGI SASONGKO

EHA, The Netherlands

Disclosure

- No conflicts of interest



Brief overview

- Tragedies of TTIDs in the 1980s-1990s
- Ig as the “driver” of PDMP collection
- Significant increases of Ig demand over time
- Shortages exacerbated by recent pandemic
- Clinical use & practices
 - In the context of limited supply, need for *more* evidence
 - Includes studies on lowest effective dose,
 - Management plans & a system of checkpoints,
 - Prioritisation in times of crises.



“Patient protection” – Nancy Di Salvo

“Patient protection from PDMPs for me means to activate a system of surveillance in the collection and handling of fractionation of plasma.

It also means to protect the patient from a system that is often not patient-focused, bureaucratic and difficult in accessing treatment.”



“Patient protection” linked to WP6 outcomes

“Patient protection from PDMPs for me means to **activate a system of surveillance** in the collection and handling of fractionation of plasma (*and usage*)

- *Create a system of documented usage including clinical efficacy*

It also means to protect the patient from a system that is often not patient-focused, bureaucratic and difficult in accessing treatment”

- *Harmonised management plan and harmonised methodology for prioritisation plan*
- *Involve patient representatives in all and/or key steps of this process, and synergize existing initiatives!*



Thank you

